Prevalence of Diabetes (n = 8)
| First Author . | Country . | Ages (y) . | N . | Definition of Abnormal . | Subgroup (eg, M/F) . | Total . | Healthy . | Overweight . | Class I . | Class II . | Class III . | P . | Notes . | Weight Definitions . | Population Info . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valerio | Italy | 3–16 | 150 | FPG > 126 mg/dL or 2-h >200 mg/dL | 0 | 0 | 0 | ||||||||
| Propst | USA | Mean 12.7 | 1111 | >6.4 | 39.8 | 52.4 | <.001 | Pediatric endocrinology patients | |||||||
| Michalsky | USA | 13–19 | 242 | Diagnosis, medication, A1c ≥6.5%, FPG ≥126 mg/dL; or 2-h OGTT ≥200 mg/dL | 13.6 | 11.3 | 15.6 | 16.0 | .55 | 1: 30 < 50 BMI, 2: 50 < 60; 3: >60 | Bariatric surgery patients | ||||
| Weiss | USA | 12–17 | 1418 | ADA definitions | 0 | 0 | 0.028985507 | 0.022452504 | <.001 | ||||||
| Bar Dayan | Israel | 17 | 76732 | Type 2 | Males | 0.036% | 0.02% | 0.05% | 0.4% | 0% | <.001 | Military recruits | |||
| Females | 0.01% | 0.001% | 0.03% | 0.1% | 0% | .015 | |||||||||
| Guerrero-Romero | Mexico | 6–18 | 1534 | ≥200 mg/dL 2-h postload | 0.6 | 0.0 | 0.5 | 1.3 | |||||||
| Hadjiyannakis | Canada | 5–17 | 847 | >7.0 FPG, >11.0 OGTT | 2 | 1 | 2 | 2 | NR | Pediatric weight management program patients | |||||
| Tsao-Wu | USA | 2–5 | 154 | HgA1c >6.5% | 0 | 0 | 0 | NR | Weight management clinic patients | ||||||
| 6–11 | 880 | 1.0 | 4.0 | 4.0 | NR | Weight management clinic patients | |||||||||
| 12–17 | 1004 | 2.0 | 1.4 | 6.2 | NR | Weight management clinic patients |
| First Author . | Country . | Ages (y) . | N . | Definition of Abnormal . | Subgroup (eg, M/F) . | Total . | Healthy . | Overweight . | Class I . | Class II . | Class III . | P . | Notes . | Weight Definitions . | Population Info . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valerio | Italy | 3–16 | 150 | FPG > 126 mg/dL or 2-h >200 mg/dL | 0 | 0 | 0 | ||||||||
| Propst | USA | Mean 12.7 | 1111 | >6.4 | 39.8 | 52.4 | <.001 | Pediatric endocrinology patients | |||||||
| Michalsky | USA | 13–19 | 242 | Diagnosis, medication, A1c ≥6.5%, FPG ≥126 mg/dL; or 2-h OGTT ≥200 mg/dL | 13.6 | 11.3 | 15.6 | 16.0 | .55 | 1: 30 < 50 BMI, 2: 50 < 60; 3: >60 | Bariatric surgery patients | ||||
| Weiss | USA | 12–17 | 1418 | ADA definitions | 0 | 0 | 0.028985507 | 0.022452504 | <.001 | ||||||
| Bar Dayan | Israel | 17 | 76732 | Type 2 | Males | 0.036% | 0.02% | 0.05% | 0.4% | 0% | <.001 | Military recruits | |||
| Females | 0.01% | 0.001% | 0.03% | 0.1% | 0% | .015 | |||||||||
| Guerrero-Romero | Mexico | 6–18 | 1534 | ≥200 mg/dL 2-h postload | 0.6 | 0.0 | 0.5 | 1.3 | |||||||
| Hadjiyannakis | Canada | 5–17 | 847 | >7.0 FPG, >11.0 OGTT | 2 | 1 | 2 | 2 | NR | Pediatric weight management program patients | |||||
| Tsao-Wu | USA | 2–5 | 154 | HgA1c >6.5% | 0 | 0 | 0 | NR | Weight management clinic patients | ||||||
| 6–11 | 880 | 1.0 | 4.0 | 4.0 | NR | Weight management clinic patients | |||||||||
| 12–17 | 1004 | 2.0 | 1.4 | 6.2 | NR | Weight management clinic patients |
ADA, American Diabetes Association; FPG, fasting plasma glucose; NR, not reported; OGTT, oral glucose tolerance test.